HomeTrialNCT05676931
🔬NCT05676931Phase 2ACTIVE NOT RECRUITING

Study With Various Immunotherapy Treatments in Participants With Lung Cancer

Study Summary

The purpose of this study is to assess the objective response rate (ORR) of immunotherapy-based combination therapy and to assess the safety and tolerability of immunotherapy-based combination therapy.

View on ClinicalTrials.gov ↗
Study Details
Enrollment400 participants
Primary Completion
Lead SponsorGilead Sciences
Data Retrieved2026-04-11 02:55:27.113387+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.